May 14, 2021

Chronic pain is a common but debilitating late effect for many patients with cancer. When undertreated, patients may experience negative functional, mental, and cancer-related outcomes. Although opioids are often effective for managing cancer pain, they may not be appropriate for some patients and others may struggle to access them because of the opioid crisis. The need for nonpharmacologic pain management options is critical. 

May 14, 2021

The American Cancer Society, along with 14 other healthcare groups advocating for increased access to care, filed an amicus curiae—Latin for “friend of the court”—urging the U.S. Supreme Court to deny state imposition of engagement requirements, like monthly community service, for Medicaid beneficiaries. The U.S. Supreme Court is likely to spend spring deliberating and convey a judgment before the end of summer.

May 13, 2021

Breast, prostate, colorectal, and melanoma are the most common primary cancer sites among 58% of survivors. Advancements in immunotherapy and targeted therapies have significantly increased treatment options for a disease that once had very limited treatment options, markedly improving overall five-year survival rates for patients with melanoma. Yet survival rates vary depending on extent of disease (local versus metastatic) and ethnic minority disparities.

May 13, 2021

In March 2021, the U.S. Department of Health and Human Services’ Ending the HIV Epidemic initiative awarded $99 million to the Health Resources and Services Administration’s (HRSA’s) Ryan White HIV/AIDS Program. The funding will support efforts to link people who are either newly diagnosed with HIV or diagnosed but currently not in care to essential treatment and support services, helping them reach viral suppression and reduce HIV transmission.

May 12, 2021

The rate of uninsured young adults (aged 19–25) fell by more than one third between 2009 and the first quarter of 2014 following the Affordable Care Act’s (ACA’s) Medicaid expansion, according to a February 2021 report from the Urban Institute. With the expansion, young adults also reported improved overall health, increased access to care, and fewer high out-of-pocket costs. 

May 12, 2021

Pirtobrutinib, an investigational, third-generation Bruton tyrosine kinase (BTK) inhibitor, offered response rates of 60% or higher in most groups of heavily pretreated patients with chronic lymphocytic leukemia (CLL), even those who’ve received other BTK inhibitors as previous treatment, researchers reported in Lancet.

May 12, 2021

In the early 2000s, healthcare professionals began creating theoretical frameworks to better understand racial gaps in care. Two decades later, racial disparities remain across all aspects of cancer care, from clinical trials and screening to mortality rates and survivorship. Rochelle P. Walensky, MD, MPH, director of the Centers for Disease Control and Prevention (CDC), declared racism a serious public health threat.